The National Institutes of Health has awarded ValVention Inc. $350,000 to study the effectiveness of FoldaValve™ transcatheter aortic valve replacement (TAVR) system. The NIH funding will support a project to test the hypothesis that the patented sheathed inverse folding mechanism of the FoldaValve™ technology is more durable and protective of the valve’s structural integrity when compared with standard crimping methods…
![NIH awards $350,000 to ValVention Inc. to validate a new heart valve replacement system](https://valvention.com/wp-content/uploads/2022/11/2012-logo.png)
![ValVention awarded a NIH grant on FoldaValve™ TAVR system](https://valvention.com/wp-content/uploads/2022/06/valvention-awarded.jpg)
Transcatheter aortic valve replacement (TAVR) is an essential alternative to surgical aortic valve replacement (SAVR) in elderly patients with aortic valve stenosis. At the current pace, TAVR procedures are expected to increase twofold from ~163,000 in 2020 to ~289,000 in 2025, and the number of patients with severe aortic stenosis is anticipated to rise to 3.5M by 2050. ValVention Inc…